Evidence map›Paper›PMID 24768240›Full record

Trial reportOphthalmology2014

Three-year treatment outcomes in the Ahmed Baerveldt comparison study.

Keith Barton, William J Feuer, Donald L Budenz, Joyce Schiffman, Vital P Costa, David G Godfrey, Yvonne M Buys, Ahmed Baerveldt Comparison Study Group

Registry-linked trialOpen access · greenAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Ophthalmology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00376363 (Ahmed Versus Baerveldt Comparison Study), which is not on this map. Cited by 35 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 3 pooled it
22.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00376363 nacompletednot on this map

Ahmed Versus Baerveldt Comparison Study

TypeinterventionalSponsorUniversity of MiamiRan2005 to 2014Enrolled276ConditionsGlaucomaArmsAhmed implant, Baerveldt implant
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 282 citations in OpenAlex.

  1. Pooled it
  2. Aqueous shunts for glaucoma.The Cochrane database of systematic reviews · 2017
    Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. 24-Month Outcomes of Ahmed ClearPathClinical ophthalmology (Auckland, N.Z.) · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Transscleral cyclophotocoagulation with MicroPulseInternational ophthalmology · 2021
    Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 4 countries.

Keith BartonNIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital, London, United Kingdom; Division of Epidemiology and Genetics, Institute of Ophthalmology, University College London, London, United Kingdom.
William J FeuerDepartment of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, Florida.
Donald L BudenzDepartment of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina. Electronic address: dbudenz@med.unc.edu.
Joyce SchiffmanDepartment of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, Florida.
Vital P CostaDepartment of Ophthalmology, University of Campinas, São Paulo, Brazil.
David G GodfreyGlaucoma Associates of Texas, Dallas, Texas.
Yvonne M BuysDepartment of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
Ahmed Baerveldt Comparison Study Group
University of Miami · USGlaucoma Associates of Texas · USUniversidade Estadual de Campinas (UNICAMP) · BRUniversity College London · GBUniversity of North Carolina at Chapel Hill · USUniversity of Toronto · CA

Funding

Shared Equipment ModuleP30EY014801 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Dmitry V Ivanov · 2004 to 2026
$12.2M
NEI NIH HHS P30 EY014801
6 · The paper itself

Abstract

purposeTo compare 3-year outcomes and complications of the Ahmed FP7 Glaucoma Valve (AGV) (New World Medical, Cucamonga, CA) and the Baerveldt Glaucoma Implant (BGI) 101-350 (Abbott Medical Optics, Abbott Park, IL) for the treatment of refractory glaucoma.

designMulticenter, randomized, controlled clinical trial.

participantsA total of 276 patients: 143 in the AGV group and 133 in the BGI group.

methodsPatients aged 18 to 85 years with refractory glaucoma and intraocular pressures (IOPs) ≥ 18 mmHg in whom an aqueous shunt was planned were randomized to an AGV or a BGI.

main outcome measuresThe IOP, visual acuity (VA), supplemental medical therapy, complications, and failure (IOP >21 mmHg or not reduced by 20% from baseline, IOP <5 mmHg, reoperation for glaucoma or removal of implant, or loss of light perception vision).

resultsAt 3 years, IOP (mean ± standard deviation) was 14.3 ± ± 4.7 mmHg (AGV group) and 13.1 ± 4.5 mmHg (BGI group) (P = 0.086) on 2.0 ± 1.4 and 1.5 ± 1.4 glaucoma medications, respectively (P = 0.020). The cumulative probabilities of failure were 31.3% (standard error [SE], 4.0%) (AGV) and 32.3% (4.2%) (BGI) (P = 0.99). Postoperative complications associated with reoperation or vision loss of >2 Snellen lines occurred in 24 patients (22%) (AGV) and 38 patients (36%) (BGI) (P = 0.035). The mean change in the logarithm of the minimum angle of resolution VA at 3 years was similar (AGV: 0.21 ± 0.88, BGI: 0.26 ± 0.74) in the 2 treatment groups at 3 years (P = 0.66). The cumulative proportion of patients (SE) undergoing reoperation for glaucoma before the 3-year postoperative time point was 14.5% (3.0%) in the AGV group compared with 7.6% (2.4%) in the BGI group (P = 0.053, log rank). The relative risk of reoperation for glaucoma in the AGV group was 2.1 times that of the BGI group (95% confidence interval, 1.0-4.8; P = 0.045, Cox proportional hazards regression).

conclusionsImplantation of the AGV was associated with the need for significantly greater adjunctive medication to achieve equal success relative to implantation of the BGI and resulted in a greater relative risk of reoperation for glaucoma. More subjects experienced serious postoperative complications in the BGI group than in the AGV group.

Indexed as

Glaucoma Drainage ImplantsProsthesis ImplantationAdolescentAdultAgedAntihypertensive AgentsFemaleFollow-Up StudiesGlaucomaHumansIntraocular PressureIntraoperative ComplicationsMaleMiddle AgedPostoperative ComplicationsProportional Hazards ModelsAntihypertensive Agents

Identifiers

PMID24768240
PMCPMC4153410
OpenAlexW2089776048

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.